Malin (MLLNF) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 08, 2026)


MLLNF Malin Corporation PLC MLLNF
17 GF Score
Price $6.40
View Full Analysis

What is Malin 5-Year Yield-on-Cost %?

Malin MLLNF 17 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus rates MLLNF with a GF Score™ of 17/100.

Malin's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Malin's 5-Year Yield-on-Cost % or its related term are showing as below:



MLLNF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.27
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Malin  (OTCPK:MLLNF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Malin 5-Year Yield-on-Cost % Related Terms


MLLNF vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malin 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Malin's 5-Year Yield-on-Cost % falls into.


MLLNF
17GF Score
Malin Corporation PLC MLLNF
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malin 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Malin is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Malin (MLLNF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Malin and its competitors.
Is Malin's 5-Year Yield-on-Cost % too high?
Malin's current 5-Year Yield-on-Cost % is 0.00. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
Malin's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 5-Year Yield-on-Cost % is 2.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Malin and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malin's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Malin (MLLNF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score

Get the complete analysis for MLLNF

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.40
Price